Encouragingly, another study has shown that an ultralow dose of DPI can safely suppress colitis-associated CRC [54]; therefore, DPI-like NADPH oxidase inhibitors have the potential to suppress NETs formation and tumor progression in CRC. The gene discussed is FMO5; the disease is colitis.